Amundi
RXRX icon

Amundi’s Recursion Pharmaceuticals RXRX Stock Holding History

Amundi’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,401
Closed -$11.5K – 2079
2025
Q1 		$11.5K Buy
2,401
+128
+6% +$933 ﹤0.01% 1878
2024
Q4 		$16.5K Sell
2,273
-68,502
-97% -$461K ﹤0.01% 1897
2024
Q3 		$456K Sell
70,775
-6,911
-9% -$49.5K ﹤0.01% 1450
2024
Q2 		$571K Buy
77,686
+6,064
+8% +$52.9K ﹤0.01% 1325
2024
Q1 		$530K Buy
71,622
+15,065
+27% +$168K ﹤0.01% 1414
2023
Q4 		$758K Sell
56,557
-32,005
-36% -$228K ﹤0.01% 1371
2023
Q3 		$565K Buy
88,562
+32,662
+58% +$326K ﹤0.01% 1395
2023
Q2 		$413K Buy
55,900
+51,660
+1,218% +$361K ﹤0.01% 1425
2023
Q1 		$27.3K Sell
4,240
-2,949
-41% -$23.4K ﹤0.01% 1944
2022
Q4 		$56.9K Buy
7,189
+2,949
+70% +$28.9K ﹤0.01% 1680
2022
Q3 		$49K Buy
+4,240
New +$42.9K ﹤0.01% 1673

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Amundi's RXRX Position: Q2 2025 in Review

Amundi sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 2,401 shares — an estimated $11.5K sold.

Amundi first reported a position in RXRX in Q3 2022 and held it in 11 quarters. The position peaked at $758K in Q4 2023. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Amundi reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 2,401 Recursion Pharmaceuticals shares in Q2 2025, an estimated $11.5K.
  • Amundi first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Amundi's Recursion Pharmaceuticals position peaked at $758K in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.